the COMBAT-COVID-19 Pilot Study

Summary

the COMBAT-COVID-19 Pilot Study is a clinical trial^[1].

Key Facts

• the COMBAT-COVID-19 Pilot Study is in the country of United States^[2].
• the COMBAT-COVID-19 Pilot Study's instance of is recorded as clinical trial^[3].
• the COMBAT-COVID-19 Pilot Study's start time is recorded as +2020-04-23T00:00:00Z^[4].
• the COMBAT-COVID-19 Pilot Study's end time is recorded as +2021-03-31T00:00:00Z^[5].
• the COMBAT-COVID-19 Pilot Study's main subject is recorded as severe acute respiratory syndrome^[6].
• the COMBAT-COVID-19 Pilot Study's number of participants is recorded as {'unit': '1', 'amount': '+70'}^[7].
• the COMBAT-COVID-19 Pilot Study's title is recorded as COlchicine in Moderate Severity Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)^[8].
• the COMBAT-COVID-19 Pilot Study's short name is recorded as COMBAT-COVID19^[9].
• the COMBAT-COVID-19 Pilot Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• the COMBAT-COVID-19 Pilot Study's ClinicalTrials.gov ID is recorded as NCT04363437^[11].
• the COMBAT-COVID-19 Pilot Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+120'}^[12].
• the COMBAT-COVID-19 Pilot Study's research intervention is recorded as gloriosine^[13].
• the COMBAT-COVID-19 Pilot Study's clinical trial phase is recorded as phase II clinical trial^[14].
• the COMBAT-COVID-19 Pilot Study's research subject recruitment status is recorded as recruiting^[15].
• the COMBAT-COVID-19 Pilot Study's study type is recorded as interventional study^[16].